Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list

Autor: Debbie L. Shawcross, Samuel Lim, Shayon Salehi, Varuna Aluvihare, Michael A. Heneghan, Nigel Heaton, Thomas H. Tranah, Vishal C. Patel

Publikováno v: Salehi, S, Tranah, T H, Lim, S, Heaton, N, Heneghan, M, Aluvihare, V, Patel, V C & Shawcross, D L 2019, ' Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list ', Alimentary Pharmacology & Therapeutics, vol. 50, no. 4, pp. 435-441 . https://doi.org/10.1111/apt.15326
Alimentary Pharmacology & Therapeutics

BACKGROUND: Rifaximin reduces the risk of overt hepatic encephalopathy (HE) and is associated with significant reductions in hospitalisations and 30-day readmissions.AIM: To examine the outcomes of patients listed for liver transplantation with a dia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7de17f29d0e63044a633e04433f58102
https://doi.org/10.1111/apt.15326

P69 NEXIT: Needle exchange initiative targeting hepatitis C (HCV) incidence in people who inject drugs (PWID) – phase 1

Autor: Shayon Salehi, Stuart McPherson, Victoria Rowell, Athar Saeed, Kasia Tylmanowska, Tamara Robinson, Tracey Kemp

Publikováno v: Abstracts.

Background Injecting drug use accounts for ~90% of HCV infections in the UK. Needle and Syringe Programs (NSPs) present a key opportunity for early detection of incident HCV infection in active injectors. Despite this, there are no clear pathways for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a81b3510711c08ee2daf5bc1b14299e
https://doi.org/10.1136/gutjnl-2020-basl.79

PTU-007 A retrospective multicentre study comparing infliximab and adalimumab for maintenance of remission in ulcerative colitis

Autor: Jimmy K. Limdi, Shadab Nayeemuddin, Shayon Salehi, Christian P. Selinger, Paul Blaker, Bu Hayee, Michael Colwill, Alexandra Kent, Victoria T. Kronsten, Glyn Scott, Guy Chung-Faye, Lulia Al-Hillawi, Patrick Dubois

Publikováno v: IBD.

Introduction Anti-tumour necrosis factor (TNF) therapy has revolutionised ulcerative colitis (UC) treatment, particularly in moderate-to-severe disease. However, these drugs tend to perform less well in the maintenance of remission. Route of administ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::df5c67f57902397dab5dba2e0819d98f
https://doi.org/10.1136/gutjnl-2018-bsgabstracts.129